ESR1 and cancer: In this context, several clinical trials are evaluating the safety and efficacy of next-generation SERDs—including elacestrant (RAD1901) (57, 58), camizestrant (AZD9833) (59), imlunestrant (LY3484356) (29, 60, 61), and giredestrant (GDC-9545) (62)—either as monotherapy or in combination with other anti-cancer agents, for targeting both ESR1 wild-type and mutant ER+/HER2− locally advanced or MBC.